The Interim Report 3rd Quarter 2020 for DanCann Pharma A/S is hereby enclosed
CEO of DanCann Pharma A/S, Mr. Jeppe Krog Rasmussen, states: “Overall, this Q3 2020 report reflect the ongoing development phase that the company is undergoing. This interim report is also our first opportunity to send our gratitude to all of you who have chosen to follow our journey and participate in the IPO. We have an exciting future ahead of us and we are now a few steps closer to realizing our vision.The period for Q3 2020 largely reflects the large and (time) demanding work leading up to our IPO – which we completed with great success where our IPO was subscribed to approx. 183